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Available online 28 December 2015In gain-of-function STAT1mutations, chronic mucocutaneous candidiasis disease (CMCD) represents the pheno-
typic manifestation of a complex immunodeﬁciency characterized by clinical and immunological heterogeneity.
We aimed to study clinical manifestations, long-term complications, molecular basis, and immune proﬁle of pa-
tients with dominant CMCD.We identiﬁed nine patients with heterozygous mutations in STAT1, including novel
amino acid substitutions (L283M, L351F, L400V). High risk of azole-resistance was observed, particularly when
intermittent regimens of antifungal treatment or use of suboptimal dosage occurs.We report a case of Cryptococ-
cosis and various bacterial and viral infections. Risk of developing bronchiectasis in early childhood or gradually
evolving to chronic lung disease in adolescent or adult ages emerges. Lymphopenia is variable, likely progressing
by adulthood.We conclude that continuous antifungal prophylaxis associated to drugmonitoringmight prevent
resistance to treatment; prompt diagnosis and therapy of lung disease might control long-term progression;
careful monitoring of lymphopenia-related infections might improve prognosis.
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In 2011, autosomal dominant gain-of-function (GOF) mutations in
signal transducer and activator of transcription 1 (STAT1) gene have
been identiﬁed as a cause of chronicmucocutaneous candidiasis disease
(CMCD) [1,2]. To date,more than 100 patients have been reported, with
37 different mutations affecting the coiled–coiled (CCD) or the
DNA-binding (DBD) domains of STAT1. This transcriptional activator
plays a major role in various signaling pathways, particularly of IFNs,
IL-27, IL-21, IL-6, and IL-17 immunity [3,4]. STAT1 loss-of-function
(LOF) mutations were already known to account for rare autosomal
recessive (AR) immunodeﬁciencies [5], resulting respectively in fatal
mycobacterial and viral diseases (when complete gene deﬁciency
occurs [6]), or milder phenotypes (when deﬁciency is partial [7]).
Autosomal dominant (AD) LOF mutations were identiﬁed as a cause of
Mendelian susceptibility to mycobacteria infections [8]. GOF-STAT1
mutations were ﬁrstly described among patients affected with severe
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mune diseases; life-threatening conditions such as squamous-cell
carcinoma, cerebral and, recently, aortic aneurysms [9] were also rarely
reported. Disseminated fungal (coccidioidomycosis, histoplasmosis,
mucormycosis) and viral (herpes virus family, a case report of orf virus)
infections were also described [10–13]. Mutations of STAT1 have been
identiﬁed by next generation sequencing also in patients with IPEX (im-
mune dysregulation, polyendocrinopathy, enteropathy, X-linked)-like
features [14], and in patients with severe, fatal phenotypes resembling
combined immunodeﬁciency [10,15]. Any evidence of any genotype–
phenotype correlation is emerging, and data about long-term morbidity
and prognosis may be controversial. Herein, we report nine
patients diagnosedwith previously reported and novel GOF-STAT1muta-
tions, showing large heterogeneity for age distribution and phenotypes.
2. Material and methods
2.1. Patients
We report nine patients whowere diagnosed as affectedwith CMCD
and evaluated for genetic analysis and in vitro functional studies from
their peripheral blood, according to approved protocols of Spedali Civili
in Brescia, Italy. Cases are described in details in [16]. Written informed
consent was obtained from all patients or their parents (for minors),
and for healthy controls. Medical history and clinical data were retro-
spectively collected from medical records. In all patients extended
immunological assessment was performed. For patients under the
care of the Department of Brescia a pulmonary evaluation, including
assessment of pulmonary function tests and imaging, was carried out.
2.2. Molecular genetic analysis
Whole exome sequencing (WES) was performed at Children's Mercy
Hospital and Clinics, Kansas City, Centre for Pediatric Genomic Medicine
(Professor Kingsmore Stephen F) for P1. STAT1mutationwas subsequent-
ly conﬁrmed by Sanger sequencing in both P1 and his mother P2. In pa-
tients P3–P9 Sanger sequencing was used to analyze STAT1. DNA was
isolated from whole blood using QIAamp DNA Blood Mini Kit (Qiagen).
STAT1 gene was ampliﬁed by PCR and products were sequenced using
BigDye Terminator Kit (Applied Biosystems). Sequences were analyzed
with 310 Genetic Analyzer (Applied Biosystems). Sequence variants
were identiﬁed relative to a reference sequence, GenBank accession no.
ENST00000361099 for the STAT1 cDNA, in which the c.1 position corre-
sponds to the Aof theATG translation initiation codon.Mutations are des-
ignated as recommended by den Dunnen and Antonarakis [17].
2.3. Analysis of phosphorylated STAT1 (pSTAT1) by ﬂow cytometry
Peripheral blood was left unstimulated and stimulated with IFNγ
(1000 U/ml), or IFNα (40,000 U/ml), for 30 min. Cells were lysed,
permeabilized, and stained, as indicated by the manufacturer (BD
Phosﬂow). Speciﬁc phycoerythrin-labeled antibody for phosphorylated
STAT1 (pSTAT1) (pY701; BD Bioscences) was used. pSTAT1 was
evaluated in both lymphocyte and monocyte gates. Cells were acquired
using FACSCalibur (BD Bioscence) and analyzed by FlowJo version 7.5
Software (TreeStar).
2.4. Cytoplasmic and nuclear extracts preparation, Western blot and EMSA
After stimulation with IFNγ or IFNβ for 30 min, cells were lysed in
cold buffer (150mMNaCl, 50 mMTris–HCl pH 7.4, 1% NP40, and prote-
ase inhibitors -Roche-containing 0.2 μg of aprotinin, leupeptin and
1 mmol/L of sodium orthovanadate) on ice for 15 min. For Western
blot analysis, cytoplasmic extracts were resolved on 8% polyacrylamide
and subjected to immunoblots by standard procedures. Nitrocellulose
membranes were ﬁrst blocked for 1 h at room temperature in TBSTcontaining 5% BSA, and then incubated overnight at 4 °C with speciﬁc
primary Abs (pSTAT1, STAT1) in the same buffer. Antibodies against
phospho-tyrosine STAT1were purchased from Cell Signaling Technolo-
gies (Denver, MA, USA). Antibodies against total STAT1 (sc-346) were
obtained from Santa Cruz, and antibodies against β-actinwere obtained
from Sigma-Aldrich. Detection was carried out using HRP-conjugated
anti-mouse or anti-rabbit IgG (Amersham Biosciences), and revealed
using ECL system (Amersham Biosciences). For EMSA, after stimulation
with IFNγ and/or IFNβ for 30min, EBV transformed B cells (5 x 106/con-
dition)were diluted in ice-cold PBS and centrifuged twice at 300 X g for
5min at 4 °C. Nuclear extractswere prepared using amodiﬁcation of the
method of Dignam et al. [18]. Transcription factor-binding analyses
were performed as described previously [18]. Nuclear extracts were in-
cubated in binding buffer in the presence of the labeled oligonucleotide
STAT-binding probe from the GRR element locatedwithin the promoter
of the FcγRI/CD64 gene (5-CTTTTCTGGGAAATACATCTCAAATCCTTGAA
ACATGCT-3) or from the interferon-stimulated response element
(ISRE) (5-GATCGGGAAAGGGAAACCGAAACTGAA-3).
2.5. Mutagenesis assay
eGFP STAT1 WT vector (Addgene) was used to obtain mutated
STAT1 form carrying L351F and L400V variants. Mutations were gener-
ated by site direct mutagenesis QuikChange Site-Directed Mutagenesis
Kit (Agilent Technologies).
2.6. Luciferase reporter assay
U3C cells were seminated into 96-well plates (1 X 104/well) and
transfected with 100 ng/well reporter plasmids and plasmids carrying
alleles of STAT1 (L351F and L400V) or amock vectorwithArrest-in (Ther-
mo Scientiﬁc). After 6 h, cells were transferred into medium containing
10% FBS and cultured for 24h. Cells were stimulatedwith IFNγ at different
concentration (10, 100, 1000 UI/ml), and IL-27 (100 ng/ml) for 16h. Lucif-
erase production was assesed with Dual-Glo luciferase assay system
(Promega) and normalized with respect to Renilla luciferase activity.
Data are expressed as fold inductions with respect to unstimulated cells.
2.7. Statistical analysis
Statistical signiﬁcance of in vitro immunological studies was
analyzed by nonparametric two-side Mann–Whitney U-test with 95%
conﬁdence bounds. For all analyses p b 0.05 was considered statistically
signiﬁcant. Statistical analyses were performed using GraphPad Prism
Version 5.0 (GraphPad Software, San Diego, CA).
3. Results
3.1. Genetic ﬁndings
We identiﬁed a novel familial STAT1 mutation (L283M) in P1 (by
WES) and in his mother P2. Other two previously unreported sporadic
mutations were detected respectively in P3 and P9 (L351F), and in P6
(L400V). P3 had been previously analyzed for AIRE (autoimmune regu-
lator) gene, showing a heterozygous variation 769C N T (R257X) he
inherited from his healthy mother. Other mutations were: T385M in
P4 and P5 [19], A267V in P7 [2], and T387A in P8 (Pignata personal
communication; Higgins et al. [20]). All are heterozygous missense
mutations (Table 1). Novel STAT1 mutations affect both CCD and DBD
domains.
3.2. Novel mutations result in increasing STAT1 phosphorylation
We investigated IFNα- and IFNγ-induced pSTAT1 by cytometry
from peripheral blood mononuclear cells (PBMCs) of our patients
compared to healthy controls (Fig. 1 in [16]). Overall, we observed
Table 1
STAT1mutations in CMCD patients.
Sex Age (years) Mutation (c.DNA) Mutation (aa change) Exon Affected domain
P1 Male 11 c.(847 T N A) L283M Exon 10 CCD
P2 Female 45 c.(847 T N A) L283M Exon 10 CCD
P3 Male 33 c.(1441 G N T) L351F Exon 12 DBD
P4 Male 15 c.(1542 C N T) T385M Exon 14 DBD
P5 Male 10 c.(1542 C N T) T385M Exon 14 DBD
P6 Female 7 c.(1198 C N G) L400V Exon 14 DBD
P7 Female 14 c.(801 T N A) A267V Exon 10 CCD
P8 Male 18 c.(1159 A N G) T387A Exon 14 DBD
P9 Female 8 c.(1441 G N T) L351F Exon 12 DBD
CMCD= chronic mucocutaneous candidiasis disease; aa = amino acid; CCD = coiled-coil domain; DBD = DNA-binding domain.
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IFNγ stimulation, in CD14+ monocytes (**p b 0.01), and IFNα stimula-
tion, in CD3+ lymphocytes (***p b 0.001), also conﬁrmed for novel
STAT1mutations (P1 and P2, P3 and P9, P6). Our results are consistent
with data of published studies and conﬁrm for novel heterozygous
alleles the association with a dominant phenotype of gain of STAT1
phosphorylation and function.
3.3. L351F and L400V variants lead to a gain of STAT1 function
We analyzed pSTAT1 in Epstein–Barr Virus (EBV)-transformed lym-
phoblasts of P3 carrying the novel L351F mutation. As illustrated in
Fig. 2A, Western blot showed that STAT1 level was normal in patient
cells. pSTAT1 had been undetectable in unstimulated cells derived
from P1 and P6, and its level had increased in response to both IFNγ-
or IFNβ-stimulation (data not shown). In order to prove the gain of
function of L351F variant, P3 EBV-transformed lymphoblasts were
treated with IFNβ or IFNγ in the presence of the 32P-labeled oligonucle-
otide STAT-binding probe derived from the IFNγ response region, or
type I ISREs. In the presence of both probes, we observed that treatment
with IFNs resulted in increased STAT1-binding activity to DNA (Fig. 2B).
Moreover, novel mutations L351F (P3 and P9) and L400V (P6) were
evaluated by transfection of STAT1-deﬁcient U3C ﬁbrosarcoma cells
with STAT1mutants constructs obtained by site-directed mutagenesis.
Responses to cytokine stimulation were investigated by measuring
the luciferase activity of the reporter gene under the control of theTable 2
Clinical and laboratory features of nine patients with STAT1-CMCD.
Age
at
onset
Age at
diagnosis
CMCD Treatment
resistance
Bacterial Infections Viral infections
P1 1 yr 9 yrs + + URTI, pneumonias None
P2 1 yr 43 yrs + + URTI, pneumonias, skin
abscesses
None
P3 6 mo 28 yrs + − URTI, pneumonias, otitis
media, skin abscesses,
Leihmaniasis,
Cryptococcosis
Recurrent
molluscum, skin
HPV
P4 5 yrs 14 yrs + − URTI, pneumonias None
P5 2 mo 9 yrs + + URTI, pneumonias, otitis
media, sepsis
None
P6 2 yr 7 yrs + − URTI, pneumonias, otitis
media
None
P7 6 mo 14 yrs + − URTI, pneumonias None
P8 7 yrs 17 yrs + − Parodontitis, skin
abscesses, suppurative
cyclid infection
Severe chicken
pox, recurrent
herpetic
infections
P9 5 mo 8 yrs + +/− Pneumonia, episcleritis Recurrent zoster
and herpetic
infections
“+”=present; “−”=absent; NK=not known; yr.(s)= year(s);mo=months; CMCD=chr
human papilloma virus; SLE = systemic lupus erythematosus; ANA = antinuclear antibody; dγ-activated sequence (GAS) promoter. After stimulation with IFNγ or
IL27, cells transfected with L351F or L400V alleles responded stronger
than those transfected with wild-type allele. In addition, stimulation
with increasing concentrations of IFNγ (10, 100, 1000 U/ml, respective-
ly) resulted in two to ﬁve times stronger responses in cells transfected
with novel mutant alleles (Fig. 2D). These results demonstrated how
novel heterozygous alleles are GOF for GAS-dependent cellular
responses to IFNγ.
3.4. A broad spectrum of infections may manifest beyond chronic
candidiasis
3.4.1. Fungal and parasite infections
All patients (mean age 17-year-old, median 14-year-old) presented
with recurrent or chronic infection with Candida albicans since early
childhood (median age at onset b1-year-old) (See Table 2). Oropharyn-
geal candidiasis manifested in all cases at onset, 5 patients (55%) devel-
oped nail infection by their ﬁrst decade, 4 patients (45%) had
oesophageal candidiasis by their second decade, while skin and genital
candidiasis were reported in 2 (P1 and P6) and 1 (P7) patients, respec-
tively. In P4 candidiasis manifested only in a mild form, as oral thrush
recurring during antibiotic therapy, well responding to topical antifun-
gal medication (miconazole). Mucocutaneous candidiasis was treated
with oral azole antifungal drugs (i.e. ﬂuconazole, itraconazole,
voriconazole), while treatment of oesophageal candidiasis in P2, P3
and P5 required intravenous antifungal therapy (i.e. ﬂuconazole,Bronchi-ectasis Hypo-thyroidism Other autoimmune
manifestations
Lympho-penia Poor
vaccine
response
− + None − −
+ − None + +
+ + SLE-like skin
disease, ANA and
ds-DNA antibody
positivity
+ +
+ − Vitiligo, ANA
positivity
+/− +
− − None +/− −
+ − None − −
− − None +/− −
NK − None − −
NK + None − −
onicmucocutaneous candidiasis disease; URTI= upper respiratory tract infections; HPV=
s= double-strand.
Table 3
Pulmonary ﬁndings, current treatment and results of last spirometry of GOF-STAT1 patients.
Age (yr) Chronic Lung
Disease
Site of bronchiectasis Age at diagnosis
(yr)
Respiratory physiotherapy Age at
starting
(yr)
FVC
L/%pred
FEV1
L/%pred
FEV1/FVC
%
FEF
25–75%
L/s
P1 11 − NA NA − NA 2.26/96 2.13/106 94 NK
P2 45 + L lower lobe, lingula 21 PEP-mask device + short acting bronchodilators,
2 times per day, regularly
30 3.05/88 2.62/84 81 3.42
P3 33 + L lower lobe, lingula 10 PEP-mask device + short acting bronchodilators,
2 times per day, intermittently
12 3.05/68 2.17/58 71 1.49
P4 15 + L lower lobe, lingula,
R middle lobe
14 PEP-mask device + short acting bronchodilators,
3 times per day, regularly
14 3.54/92 2.66/80 75 2.19
P5 10 − NA NA PEP-mask device + short acting bronchodilators,
initially intermittently (i.e. during pulmonary
infection), then 2 times per day, regularly
4 1.76/92 1.66/98 94 2.72
P6 7 + L lower lobe, lingula,
R middle lobe
6 PEP-mask device + short acting bronchodilators,
2 times per day, regularly
6 NP NP NP NP
P7 14 − NA NA − NA 2.76/80 2.72/90 99 4.88
P8 18 − NA NA − NA NP NP NP NP
P9 8 − NA NA − NA NP NP NP NP
“+”=present; “−”=absent; yr. = years; NA=not applicable; NK=not known; L= left; R= right; PEP= positive expiratory pressure; FVC= forced vital capacity; L= liter; pred=
predicted; FEV1 = forced expiratory volume in 1 s; FEF = forced expiratory ﬂow; NP = not performed.
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zole, itraconazole, or voriconazole). All patients were started on continu-
ous dosing-regimen: ﬂuconazole was initially the drug of ﬁrst choice for
most of the patients, but changed to itraconazole in P1, P2, P3, and P5 fol-
lowing clinical (persistent or relapsing mucocutaneous candidiasis) and
microbiological evidence of resistance. The latter has been monitored
with susceptibility testing performed on Candida spp. cultured fromFig. 1.GOF-STAT1mutation is associatedwith increased STAT1 activation. A and B. Summary of
in IFNγ-stimulatedmonocytes (B). C and D. Intracellular staining of phosphorylated tyrosine 70
not stimulated and IFNγ-induced monocytes (D). Each experiment was independently repe
intensity ﬂuorescence; HD = healthy donor.oropharyngeal swabs, routinely performed in the majority of patients
with clinical evidence of infection, and resulting in a minimal inhibitory
concentration (MIC) forﬂuconazole from8 to 256mcg/ml in resistant pa-
tients. In addition, themajority of patients have been followedwithmon-
itoring of serum azole level to concurrently adjust the dosage of
medication (target of N500 ng/ml when prophylaxis or N1000 ng/ml
when therapy regimen, respectively). We observed, speciﬁcally in P2,mean intensity ﬂuorescence (MFI) of pSTAT1 in T-lymphocytes inducedwith IFNα (A) and
1 STAT1 (P701-YSTAT1) in not stimulated (NS) and IFNα-induced T lymphocytes (C), and
ated at least three times for each patient: representative cases are shown. MFI = mean
Fig. 2.Novelmutants L351F and L400V STAT1 alleles are dominant for GAS-dependent cellular responses. A and B. Response of P3 EBV-B cells (L351F) byWestern blot (A) and EMSA (B). C
and D. Induction of GAS-dependent reporter gene transcription activity in U3C cells transfectedwithWT ormutant alleles of STAT1 (L351F and L400V): cells were stimulatedwith IFNγ or
IL27 (C) and increasing doses of IFNγ (D). Results derived from one representative experiment of three independent experiments. HD = healthy donor; NS = not stimulated.
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oropharynx, nails, esophagus), that intermittent regimen treatment and
use of suboptimal dosage predisposed to persistent infection and devel-
opment of resistance to azoles (initially limited to ﬂuconazole, but ex-
tended to itraconazole and voriconazole, with current sensitivity for
posaconazole). Interestingly, in addition to Candida infection, P3 also de-
veloped an intracellular pathogen infectionwithCryptococcus neoformans
(Fig. 3), presenting as disseminated granulomatous necrotizing lymphad-
enitis at the age of 14 years, well responding to intravenous ﬂuconazole.
Moreover, at the age of 28 years, the same patient suffered from dissem-
inated visceral leishmaniasis, was initially treated with amphotericin B,
but the latter caused drug-related nephropathy, and was replaced with
miltefosﬁne.
3.4.2. Bacterial infections
The majority of patients (no relevant episodes in P8 history) had a
history of recurrent upper respiratory tract infections and experienced
pneumonias (See Table 2), variably associated with bouts of obstructive
bronchitis, since their childhood, often requiring hospitalization for in-
travenous antibiotic therapy. Haemophilus inﬂuenzae, Streptococcus
pneumoniae, or Staphyloccocus aureus were the pathogens usually de-
tected in the sputum, when culture was available. Moreover, some pa-
tients had recurrent pulmonary exacerbations with opportunisticpathogens. P2, P4 and P6 had been suffering from intermittent infection
with Pseudomonas aeruginosa; in P4 bronchopneumonia with Serratia
marcescens recurred twice when he was 14-year-old. The recurrence
of pulmonary infections has currently led to permanent lung damage
in 4 patients of our cohort (P2, P3, P4, P6), as diagnosed by chest
computed tomography (CT)-scan (Pulmonary ﬁndings summarized in
Table 3; see Fig. 2 in [16]). All patients had been commenced on
pneumonologist follow-up, together with regular respiratory physio-
therapy, in order to enhance clearance of bronchial secretion and con-
trol pulmonary exacerbations [21–23]. The analysis of spirometry
results [24] in these patients developing chronic lung disease shows a
tendency to develop obstructive pulmonary disease, with a forced expi-
ratory volume in 1 s (FEV1) generally below normal range, associated to
a reduction in the forced expiratory ﬂow during the interval 25–75% of
the forced vital capacity (FEF 25-75%). These changes of FEF 25-75% con-
stitute a sensitive parameter in the detection of obstructive small airway
disease [25]. Speciﬁcally, P4 has experienced a rapid decline of his lung
function (Forced Vital Capacity -FVC- from3.17 to 2.17 L, FEV1 from2.35
to 1.68 L, and FEF 25-75% from 1.78 to 1.49 L/s) in a eight-months time
characterized by pulmonary exacerbationswith Serratia: in this patient,
in few months, we have currently observed a return of his pulmonary
tests to normal values (FVC 3.54 L, FEV1 2.66 L, FEF 25-75% 2.19 L/s)
and no pulmonary exacerbations, likely related to the increase of daily
Fig 3. Necrotizing granulomatous lymphadenitis (blue arrow), containing numerous mucicarmine-positive cryptococci (red arrow) (Hematoxylin-Eosin; inset: mucicarmine stain).
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azithromycin, following the rationale of a reduction of pulmonary
exacerbations in patients with non-cystic ﬁbrosis bronchiectasis by
using low-dose macrolide [26].
Among other bacterial infections, our cohort features abscesses and
sepsis. Three patients (P2, P3, and P8) suffered from skin abscesses: in
P3 a coagulase negative Staphylococcus was detected and infection re-
solved after intravenous antibiotic and surgical excision, while P8 had
recurrent S. aureus-positive abscesses requiring systemic antibiotic
treatment, and P2 was alternately treated with oral or intravenous
antibiotics for recurrent boils. P5 had a Streptococcus viridians sepsis,
concomitantly to a Pneumocystis jirovecii pneumonia, at the age of four
months (lymphocyte subsets had been performed few months after
the acute episode with normal results), while P2 sepsis was caused by
Difteroides spp. when 28-year-old.
3.4.3. Viral infections
We observed abnormal response to viral infections in some patients
(See Table 2). P8 had varicellawith severe involvement ofmucosa at the
age of 8 years. Both P8 and P9 presentedwith recurrentmucocutaneous
infections with herpes simplex viruses and severe episodes of varicella-
zoster infection. P3 had molluscum and human papilloma virus cutane-
ous lesions.
3.5. Autoimmune manifestations may be part of a heterogeneous
phenotype
In our cohort, hypothyroidism manifested in three patients (P1, P3,
and P9; see Table 2): all cases had negative auto-antibodies
(antithyroglobulin, antithyroid peroxidase, anti thyroid-stimulating
hormone -TSH- receptor antibody), but typically presented a
dysomogeneous ultrasound appearance of the gland. All patients started
the treatment of hypothyroidismwith levothyroxine by their ﬁrst decade
of life. On autoimmune screening, antinuclear antibodies tested positive
in P3 (title increasing from 1:160 to 1:320) and P4 (stable title 1:320),
in P3 also associated to positivity for anti-double strand DNA antibodies
(138–122%, normal value b35%): P3 has developed Systemic Lupus
Erythematosus (SLE)-like skin face lesions, while P4 suffers from a mild
form of vitiligo. Despite cerebral vasculitis and cerebral and aorticaneurysms have been reported [19], none of our patients ever had signs
or symptoms suggesting investigation for cerebral or heart complications.
3.6. The immunological phenotype: risk of progressing lymphopenia
Analysis of lymphocyte subsets in each patient of our cohort (Fig. 4;
see Table 1 in [16]) revealed persistent lymphopenia in two adult
patients. In P2, total lymphocytes range from a maximum of 1250
cells/mmc to 810 cells/mmc (mean below 1000 cells/mmc), with low
counts of both T and B lymphocytes (normal CD4+/CD8+ ratio and NK
cell counts in the normal range). P3 developed lymphopenia in his
twenties, with total lymphocytes ranging from 700 to 1130 cells/mmc,
low numbers of CD3+ (375–730 cells/mmc), CD4+ (233–421 cells/
mmc), and CD8+ (128–272 cells/mmc) cells, but normal B cell count
(261–335 cells/mmc). Interestingly, P3 also showed low NK cells
count, that was persistently below 50 cells/mmc (11–44 cells/mmc).
In P4 we observed transitory reduction of CD4+ T cells (382 cells/mmc),
out of a speciﬁc infectious episode, in P5 low CD4+ T cells (1153 cells/
mmc) during his ﬁrst year of life, but out of his episode of sepsis, and in
P7 a single determination of low CD19+ cells (152 cells/mmc). Moreover,
lymphocyte subsets analysis in six patients showed a low percentage of
memory B cells, with reduction of both un-switched (median 3% of B
cells) and switched subsets (median 1% of B cells) (see Table 1 in [16]).
Three patients (P2, P3, P4) also had defective antibody response to tet-
anus toxoid (b0.05UI/ml),withunprotective title conﬁrmedafter booster
vaccine. Overall, serum immunoglobulin levels, TRECs, and lymphocyte
proliferation assays to mitogens did not show abnormalities (data not
shown).We observed low immunoglobulin (Ig) M level only in P1 in dif-
ferent determinations (IgM31mg/dl -range 56–261- at the age of 6 year-
old; IgM 46 mg/dl -range 61–276- at the age of 10), with normal IgG
(1040 mg/dl -range 707–1919-) and IgA (143 mg/dl -range 60–270-).
4. Discussion
4.1. Novel mutations conﬁrm the increased STAT1 phosphorylation
We describe nine patients of Caucasian origin and Italian nationality
with heterozygous GOF mutations in STAT1. Three novel mutations
were identiﬁed: L283M in the CCD, while L351F and L400V in the
Fig. 4. Lymphocyte subsets for each CMCDpatient are shown as a single value per age range. Normal ranges of lymphocyte counts, we have illustrated in the chart background,were based
on age-matched healthy control subjects. The complete series of lymphocyte counts is shown in the Table 1 in [16].
7L. Dotta et al. / Clinical Immunology 164 (2016) 1–9DBD. The underlying pathogenesis involves a gain of STAT1 phosphory-
lation resulting in a gain-of-function of GAF in response to various cyto-
kines. Consistently with previous reports, levels of pSTAT1 are high in
CD3+ and CD14+ cells, gamma-activated sequence binding activity
increases following stimulation with IFNγ, and cellular response is en-
hanced to cytokines such as IFN-α/β, IFN-γ, and IL-27, which potently
inhibit development of IL-17–producing T cells via STAT1 [1–3,27].4.2. CMCD represents the hallmark of GOF-STAT1 phenotype with high risk
of resistance to treatment
In the clinical phenotype of the majority of patients, CMCD repre-
sents the main manifestation and feature of suspicion at onset, but se-
verity largely varies from chronic recurrent and debilitating infection
to milder form, detectable after detailed questioning of medical history,
8 L. Dotta et al. / Clinical Immunology 164 (2016) 1–9or occurring only during antibiotic therapy.We show high risk of devel-
oping resistance to oral antifungal treatment, associated to high MIC to
azoles (i.e. ﬂuconazole), and resulting in chronic infectionwith Candida.
Development of antifungal resistance in our patients was not associated
to any speciﬁc STAT1 mutations. Conversely, STAT1 patients displaying
mild forms of candidiasis may suggest that genetic or environmental
factors could contribute to their susceptibility to fungal infections. In
particular, intermittent regimens of antifungal treatment or use of
azoles at suboptimal doses might favor the selection of azole-resistant
strains of Candida. Development of azole-resistance may require use of
alternative regimens including caspofungin, or liposomal amphotericin
B, that are administered by an intravenous route. In addition, case report
studies have suggested that immunomodulatory treatment with
cytokines such as granulocyte-colony stimulating factor (G-CSF) or
granulocyte monocyte-colony stimulating factor (GM-CSF) may restore
the generation of Th17 cells and parallel enhance recovery from fungal
infections [28]. However, these preliminary ﬁndings should be con-
ﬁrmed in larger cohort of patients. Until then, our study suggests that
antifungal prophylaxis with ﬂuconazole or itraconazole should be com-
menced in all patients at the time of diagnosis, regularly continued and
strictly monitored by pharmacokinetics measurements and susceptibil-
ity testing, in order to optimize control of diffuse candidiasis, prevent
developing of inadequate dose-related resistance, and guarantee
efﬁcient treatment.
4.3. A broader spectrum of infections, the occurrence of chronic lung
disease, lymphopenia, or autoimmunity may complicate the prognosis
GOF-STAT1 patientsmay typically experience also recurrent bacteri-
al infections since early childhood, and present viral diseases mainly
with herpes family viruses [12,13,15,29], causing highmorbidity and in-
creasing themortality risk. Speciﬁcally, Sherfe et al. reported of three pa-
tients who died of overwhelming viral infections (Cytomegalovirus,
Epstein–Barr virus, and Jamestown Canyon virus, respectively), inter-
estingly presenting with a combined immunodeﬁciency (CID)-like im-
munological phenotype (progressive loss of T cells and natural killer
cells, plus humoral defect). In our cohort, we observed that lymphope-
nia, manifesting with reduction in CD3+, CD4+ and CD8+ lymphocytes
subsets, may not be constantly present, but might progress by adult-
hood. Consistentwith that, carefulmonitoring ofmain lymphocyte sub-
sets could help in clinical management by early detection of patients
developing severe lymphopenia that might require to be evaluated for
hematopoietic stem cell transplantation (HSCT). Interestingly, we re-
port a reduction in both un-switched and switched memory B cells in
the majority of our patients, supporting a previous observation in the
case report by Frans et al. [30]. Currently, any genotype–phenotype cor-
relation seems consistent, even thoughwe observed same characteristic
features in patients with same mutations. Particularly, in our cohort an
increased susceptibility to viral infections manifested in patients carry-
ing L351F and T387A variants. Meanwhile, we observed how T385M
variant differently manifested in two patients with similar age and
sex: P4 suffered from severe and recurrent lower respiratory tract infec-
tions and developed bronchiectasis and chronic lung disease in his ado-
lescent age; P5 presented with early severe reﬂux disease, required
Nissen fundoplicatio, and had jatal hernia, concurrently with oesopha-
geal candidiasis. Similarly, in previous reports [30], this mutation vari-
ably presented with mainly gastrointestinal or respiratory phenotype,
but also with progressing combined immunodeﬁciency predisposing
to fatal infections [15,19,31]. For other novel mutations herein identi-
ﬁed, major phenotypic manifestations include early development of
bronchiectasis in patient carrying the L400V variant, and lymphopenia
and chronic lung disease progressing by adulthood in the familiar vari-
ant L283M. These phenotypes may add new characteristic manifesta-
tions, but are insufﬁcient to hypothesize any certain correlation with
the genotype; indeed, the paucity of reported cases likely suggests any
observed association still as serendipity. More important, we showhow lung disease represents a major complication as it may slowly
evolve by adulthood to permanent lung damage predisposing to recur-
rent pulmonary exacerbations and higher morbidity. Early recognition
of lung damage at initial stage associated to prompt aggressive treat-
ment of pulmonary infection and daily respiratory physiotherapy
might prevent progression of the disease. The role of antibiotic prophy-
laxis, including low-dose macrolide, could be controversial because of
increased risk of progressing candidiasis. Finally, autoimmune manifes-
tations represent common features of the disorder and extensive auto-
immune assessment should be regularly performed: consistently with
what previously reported, thyroidopathy represents the most common
disorder [1,19], variably onsets by theﬁrst or second decade of life, asso-
ciates to no thyroid antibody or signiﬁcant alterations of B subsets, but
gland abnormalities, supporting the hypothesis of an increased re-
sponse to type I IFNs and the role of IFNs signature in the disease [3,
32]. Recently, Oftedale et al. redeﬁned a “non-classical” form of autoim-
mune polyendocrine syndrome type 1 (APS-1) where a milder, less
penetrant autoimmune phenotype associates to dominant heterozy-
gous mutations in AIRE [33]. Even though AIRE p.R257 mutation is
known to behave in a recessive manner, further characterization could
be pursued to rule out the role of AIRE mutation in our patient P3 who
features CMCD together with a mild autoimmune phenotype.5. Conclusion
GOF-STAT1 disorder represents an emerging primary immunodeﬁ-
ciency and analysis of larger cohort of patients is warranted to better
characterize clinical and genetic heterogeneity, long-term complica-
tions, and prognosis of the disease.References
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